雷帕鸣西罗莫司片是否加入医保了

Have you joined the medical insurance? It is understood that Rapamin sirolimus tablets have been included in the National Medical Insurance Catalog (Category B) and are medical insurance drugs. However, the reimbursement ratios vary from place to place. It is recommended that patients consult the local medical insurance bureau.

Rapamune sirolimus tablets, marketed by Pfizer under the trade name Rapamune, were initially developed as a low-toxicity antifungal drug for patients undergoing kidney transplantation to prevent organ rejection. Used in combination with cyclosporine and corticosteroids. In 1977, Rapamir and Sirolimus Tablets were discovered to have immunosuppressive effects (inhibiting mTOR). In September 1999, the US FDA approved Rapamin and Sirolimus Tablets to prevent organ transplant rejection. On May 28, 2015, Rapamin and Sirolimus Tablets were approved to treat a rare lung disease, lymphangioleiomyomatosis (LAM).

Rapamin sirolimus tablets are rapidly absorbed after taking oral solution, with the average peak time after a single oral dose being approximately 1 hour; in kidney transplant recipients, the average peak time after multiple oral doses is approximately 2 hours. High-fat meals can increase the absorption of Rapamin and Sirolimus Tablets, so it is recommended that Rapamin and Sirolimus Tablets should be taken regularly with or without food. Rapamin sirolimus tablets are extensively bound to human plasma proteins (approximately 92%). Rapamin sirolimus tablets are substrates of cytochrome P450 III A (CYP3A) and P-glycoprotein (P-gp).

Treatment with rapamin and sirolimus tablets may cause harm to the fetus. Therefore, effective contraceptive measures should be taken during treatment with rapamin and sirolimus tablets and for 12 weeks after stopping. During pregnancy, rapamirumab should be used only if the potential benefits of its use outweigh the potential risks to the embryo/fetus.

Taking it for treatment may cause hyperlipidemia, which may increase blood lipids (cholesterol and triglycerides). Patients with hyperlipidemia should use this drug with caution. Patients should monitor cholesterol/lipids while receiving rapamycin sirolimus; if hyperlipidemia occurs, follow current management guidelines (diet, exercise, lipid-lowering agents). Antihyperlipidemic treatments may not be effective in achieving normal levels.

Recommended related hot articles: /newsDetail/80167.html